About: Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19
Creator	Li, Fei Grammer, Leslie Schleimer, Robert Quan, Peters, Anju Bochner, Bruce Kalhan, Ravi Stevens, Whitney Saltoun, Carol Chen, Michael Chhiba, Krishan Greenberger, Paul Guo, Amina Harris, Kathleen Huyen, Thanh Kudlaty, Elizabeth Mai, Quan Muhammad, Lutfiyya Patel, Gayatri Vu, T Yeh, Chen
Source	Elsevier; Medline; PMC
abstract	Abstract: Background The Centers for Disease Control and Prevention advises that patients with moderate-to-severe asthma belong to a high-risk group that is susceptible to severe COVID-19. However, the association between asthma and COVID-19 has not been well-established. Objective The primary objective was to determine the prevalence of asthma among COVID-19 patients in a major U.S. health system. We assessed the clinical characteristics and comorbidities in asthmatic and non-asthmatic COVID-19 patients. We also determined the risk of hospitalization associated with asthma and/or inhaled corticosteroid use. Methods Medical records of patients with COVID-19 were searched by a computer algorithm (March 1–April 15, 2020), and chart review was used to validate the diagnosis of asthma and medications prescribed for asthma. All patients were PCR-confirmed COVID-19. Demographics and clinical features were characterized. Regression models were used to assess the associations between asthma and corticosteroid use and the risk of COVID-19-related hospitalization. Results Of 1,526 patients identified with COVID-19, 220 (14%) were classified as having asthma. Asthma was not associated with an increased risk of hospitalization (RR of 0.96 [95%CI: 0.77-1.19]) after adjusting for age, sex, gender, and comorbidities. The ongoing use of ICS did not increase the risk of hospitalization in a similar adjusted model (RR of 1.39 [95%CI: 0.90-2.15]). Conclusions Despite a substantial prevalence of asthma in our COVID-19 cohort, asthma was not associated with an increased risk of hospitalization. Similarly, the use of ICS with or without systemic corticosteroids was not associated with COVID-19-related hospitalization.
has issue date	2020-06-15(xsd:dateTime)
bibo:doi	10.1016/j.jaci.2020.06.010
bibo:pmid	32554082
has license	els-covid
sha1sum (hex)	5f2f10594f0967be91306a6b6f711e1190a30131
schema:url	https://doi.org/10.1016/j.jaci.2020.06.010
resource representing a document's title	Prevalence and characterization of asthma in hospitalized and non-hospitalized patients with COVID-19
has PubMed Central identifier	PMC7295471
has PubMed identifier	32554082
schema:publication	J Allergy Clin Immunol
resource representing a document's body	covid:5f2f10594f0967be91306a6b6f711e1190a30131#body_text
is schema:about of	named entity 'asthma' named entity 'hospitalization' named entity 'Patel' named entity 'Chronic' named entity 'cohort' covid:arg/5f2f10594f0967be91306a6b6f711e1190a30131 named entity 'inhaled corticosteroids' named entity 'COVID-19' named entity 'Studies' named entity 'Asthma' named entity 'hospitalization' named entity 'COVID-19' named entity 'asthma' named entity 'Results' named entity 'group' named entity 'inhaled corticosteroids' named entity 'hospitalized' named entity 'Prevalence' named entity 'asthma' named entity 'COVID' named entity 'risk group' named entity 'Centers for Disease Control and Prevention' named entity 'asthma' named entity 'COVID' named entity 'asthma' named entity 'COVID-19' named entity 'asthma' named entity 'COVID-19' named entity 'COVID' named entity 'COVID-19' named entity 'higher risk' named entity 'Community spread' named entity 'asthma' named entity 'asthmatic' named entity 'asthma' named entity 'sensitivity analysis' named entity 'PCR' named entity 'COVID' named entity 'ethnicity' named entity 'coronavirus disease' named entity 'COVID-19' named entity 'asthma' named entity 'COVID-19' named entity 'clinical characteristics' named entity 'relative risk' named entity 'IgA deficiency' named entity 'asthmatics' named entity 'corticosteroids' named entity 'China' named entity 'asthma' named entity 'receptor' named entity 'community transmission' named entity 'COVID-19' named entity 'asthma' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'risk factors' named entity 'BMI' named entity 'RT-PCR' named entity 'comorbid' named entity 'COVID' named entity 'asthma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software